The Role of the Intensivist in the Diagnosis of Occult Cancer

Dr Neeraj Manikath , claude.ai

Abstract

Occult malignancy presents unique diagnostic challenges in the intensive care unit, where critically ill patients may manifest cancer through atypical presentations including venous thromboembolism, paraneoplastic syndromes, unexplained organ failure, or metabolic derangements. The intensivist must maintain clinical vigilance for these presentations while balancing the risks and benefits of invasive diagnostic procedures in hemodynamically unstable patients. This review examines the clinical patterns suggesting occult malignancy, the role of tissue diagnosis in febrile immunocompromised states, recognition of tumor lysis syndrome without known cancer, emerging diagnostic technologies including liquid biopsy, and the complexities of initiating oncologic therapy in critical illness. Early recognition and diagnosis can fundamentally alter management trajectories and improve outcomes in this challenging patient population.

Keywords: Occult malignancy, paraneoplastic syndromes, tumor lysis syndrome, liquid biopsy, critical care oncology

Introduction

Approximately 3-8% of intensive care unit (ICU) admissions involve patients with ultimately diagnosed but previously unrecognized malignancies.[1,2] The intersection of critical illness and occult cancer creates diagnostic complexity, as presenting symptoms often mimic sepsis, autoimmune disease, or other acute medical conditions. The intensivist occupies a unique position to recognize patterns suggesting underlying malignancy and initiate diagnostic pathways that may be life-saving. However, this must be balanced against the risks of invasive procedures in critically ill patients and the prognostic implications of cancer diagnosed in extremis.

The modern intensivist requires a framework for approaching occult malignancy that integrates classical clinical reasoning with contemporary diagnostic technologies. This review provides practical guidance for postgraduate trainees in critical care medicine navigating these diagnostic dilemmas.

The ICU Presentation of Occult Malignancy: VTE, Paraneoplastic Syndromes, and Unexplained Organ Failure

Venous Thromboembolism as a Sentinel Event

Unprovoked venous thromboembolism (VTE) represents one of the most common presentations of occult malignancy in the ICU, with 4-12% of patients with idiopathic VTE diagnosed with cancer within one year.[3] Trousseau's syndrome—migratory thrombophlebitis associated with malignancy—remains a critical clinical sign, particularly with adenocarcinomas of pancreatic, gastric, or lung origin.[4]

Clinical Pearl: Consider occult malignancy in patients presenting with:

Bilateral or migratory VTE
Resistance to anticoagulation despite therapeutic levels
Thrombosis in unusual sites (splanchnic, cerebral, upper extremity without central line)
Trousseau's triad: VTE + arterial thrombosis + non-bacterial thrombotic endocarditis
Concomitant thrombocytosis (platelets >450,000) suggesting chronic myeloproliferative disorder

Diagnostic Hack: In patients under 50 with unprovoked VTE and no family history, obtain age-appropriate cancer screening plus CA-19-9, CEA, and CT chest/abdomen/pelvis. The diagnostic yield increases significantly when D-dimer remains markedly elevated (>5,000 ng/mL) despite adequate anticoagulation.[5]

Paraneoplastic Syndromes: Remote Effects of Malignancy

Paraneoplastic syndromes affect 10-20% of cancer patients and may precede tumor diagnosis by months to years.[6] In the ICU, these syndromes often manifest as neurological, hematological, or endocrine emergencies.

Neurological Paraneoplastic Syndromes:

Lambert-Eaton myasthenic syndrome (LEMS): Progressive proximal weakness with autonomic dysfunction, associated with small cell lung cancer in 60% of cases[7]
Paraneoplastic encephalitis: Limbic encephalitis with seizures, memory impairment, psychiatric symptoms (anti-Hu, anti-Ma2, anti-NMDA antibodies)
Cerebellar degeneration: Subacute onset ataxia, dysarthria (anti-Yo, anti-Tr antibodies)
Opsoclonus-myoclonus syndrome: "Dancing eyes, dancing feet" in adults suggests neuroblastoma or small cell lung cancer

Oyster: Not all antibody-positive cases have cancer. Anti-NMDA receptor encephalitis occurs in young women with ovarian teratoma but also occurs without malignancy. The presence of additional paraneoplastic antibodies increases cancer likelihood significantly.[8]

Hematological Manifestations:

Microangiopathic hemolytic anemia with thrombocytopenia suggesting gastric adenocarcinoma
Leukemoid reaction (WBC >50,000 without leukemia) from tumor G-CSF secretion
Pure red cell aplasia with thymoma
Acquired hemophilia A (anti-factor VIII antibodies) with lymphoproliferative disorders

Endocrine Paraneoplastic Syndromes:

SIADH (most commonly small cell lung cancer)
Humoral hypercalcemia of malignancy (PTHrP secretion)
Ectopic ACTH syndrome with profound hypokalemia and metabolic alkalosis
Hypoglycemia from IGF-2 secretion by mesenchymal tumors

Clinical Pearl: The "triad of threes" for ectopic ACTH: potassium <3 mEq/L, bicarbonate >30 mEq/L, glucose >300 mg/dL with new-onset hypertension suggests small cell lung cancer or bronchial carcinoid.[9]

Unexplained Organ Failure

Hepatic Infiltration: Diffuse hepatic metastases may present as fulminant hepatic failure without known primary malignancy. Suspect when:

Marked transaminase elevation (ALT/AST >1000) with disproportionate alkaline phosphatase elevation
Hepatomegaly with heterogeneous echotexture on ultrasound
Refractory hypoglycemia from liver replacement
Primary sites include breast, lung, gastric, and pancreatic adenocarcinomas[10]

Lymphangitic Carcinomatosis: Presents as progressive dyspnea with normal or near-normal chest radiograph but profound hypoxemia. CT shows septal thickening, ground-glass opacities, and pleural effusions. Bronchoscopy may be negative; diagnosis requires transbronchial or surgical lung biopsy.[11]

Diagnostic Hack: Calculate the alveolar-arterial gradient. A-a gradient >50 mmHg on room air with clear chest radiograph should prompt consideration of lymphangitic spread, especially with known or suspected adenocarcinoma.

Bone Marrow Infiltration: Pancytopenia with circulating immature cells (leukoerythroblastic picture) suggests marrow replacement by metastatic disease, most commonly from breast, prostate, lung, or neuroblastoma.

The Role of Blind Biopsies (Liver, Bone Marrow, Skin) in the Febrile, Immunocompromised Host

Diagnostic Yield and Risk Stratification

In the febrile immunocompromised patient with unrevealing initial investigations, blind tissue biopsy may provide diagnoses ranging from opportunistic infections to occult hematological malignancies. The diagnostic yield varies by site and clinical context.[12]

Bone Marrow Biopsy:

Diagnostic yield: 30-40% in fever of unknown origin when combined with aspirate and culture[13]
Highest yield in: Hematological malignancy, hemophagocytic lymphohistiocytosis (HLH), disseminated granulomatous disease, miliary tuberculosis
Complications: <1% risk of serious bleeding with platelet count >30,000 and correction of coagulopathy

Clinical Pearl: Order bilateral bone marrow biopsies (posterior iliac crests) when suspecting metastatic disease, as sensitivity increases from 65% to 85%.[14] Send tissue for flow cytometry, cytogenetics, molecular studies, and culture for mycobacteria, fungi, and conventional bacteria.

Liver Biopsy:

Diagnostic yield: 60-70% when hepatomegaly with focal lesions present; 15-20% when diffuse infiltration without focal abnormality[15]
Indications in ICU: Unexplained cholestasis, diffuse infiltration on imaging, fever with hepatosplenomegaly
Risk mitigation: Use transjugular approach when coagulopathy (INR >1.5) or thrombocytopenia (<50,000) present; allows simultaneous hepatic venous pressure measurement

Oyster: "Normal" alkaline phosphatase does not exclude hepatic infiltration. Patients with rapid liver replacement may not mount inflammatory response sufficient to elevate alkaline phosphatase. Focus on ALT/AST pattern and imaging characteristics.[16]

Skin Biopsy:

Often underutilized but high yield in appropriate clinical contexts
Diagnostic in: Leukemia cutis, intravascular lymphoma, carcinoma erysipeloides (inflammatory breast cancer), Sweet's syndrome (acute febrile neutrophilic dermatosis)
Technique: Full-thickness punch or excisional biopsy of 4-6mm; include subcutaneous tissue

Diagnostic Hack for Intravascular Lymphoma: This rare aggressive B-cell lymphoma occludes small vessels without forming discrete masses, presenting as fever, neurological symptoms, and skin lesions. Random skin biopsy of normal-appearing skin has 35% diagnostic yield; add random bone marrow biopsy to increase sensitivity to >70%.[17]

Special Consideration: Hemophagocytic Lymphohistiocytosis

HLH represents a hyperinflammatory syndrome that may be triggered by occult malignancy (particularly T-cell lymphomas) or present as the primary manifestation of malignancy. ICU patients often meet HLH-2004 diagnostic criteria: fever, splenomegaly, cytopenias, hyperferritinemia (>500 μg/L), hypertriglyceridemia (>265 mg/dL), hypofibrinogenemia (<150 mg/dL), hemophagocytosis on marrow biopsy, decreased NK cell activity, elevated soluble CD25.[18]

Clinical Pearl: Ferritin >10,000 μg/L has 90% sensitivity and 96% specificity for HLH in adults. H-score calculator (online tool) uses nine variables to estimate HLH probability; score >169 suggests 99% probability.[19]

When NOT to Biopsy

Contraindications requiring careful consideration:

Severe coagulopathy uncorrectable by transfusion
Hemodynamic instability requiring escalating vasopressor support
Anticipated survival <48 hours regardless of diagnosis
Patient/surrogate unwilling to pursue cancer-directed therapy

Ethical Pearl: Engage early goals-of-care discussions before invasive procedures. A diagnosis of malignancy in a moribund patient may add psychological burden to families without altering care trajectory.

Interpreting Tumor Lysis Labs in a Patient Without a Known Cancer Diagnosis

Pathophysiology and Clinical Recognition

Spontaneous tumor lysis syndrome (STLS) occurs when rapidly proliferating malignancies outgrow blood supply, resulting in massive tumor cell death and release of intracellular contents. While classically associated with treatment of high-grade lymphomas and leukemias, STLS may be the presenting manifestation of occult malignancy.[20]

Cairo-Bishop Diagnostic Criteria (Laboratory TLS): Two or more of the following within 3 days before or 7 days after chemotherapy initiation:

Uric acid ≥8 mg/dL or 25% increase
Potassium ≥6 mEq/L or 25% increase
Phosphate ≥4.5 mg/dL or 25% increase
Calcium ≤7 mg/dL or 25% decrease[21]

Clinical TLS: Laboratory TLS plus one or more: AKI, cardiac arrhythmia, seizure, or death.

Spontaneous TLS: Malignancies to Consider

High-Risk Malignancies for STLS:

Burkitt lymphoma (most common cause)
Acute lymphoblastic leukemia with WBC >100,000
Diffuse large B-cell lymphoma with bulky disease (>10cm)
Acute myeloid leukemia with WBC >50,000
Small cell lung cancer with extensive disease
Rarely: solid tumors (breast, gastric) with extensive liver metastases[22]

Diagnostic Hack: The pattern matters. Hyperuricemia with hyperphosphatemia and hypocalcemia is virtually pathognomonic for tumor lysis. Other causes of AKI elevate uric acid but don't typically cause severe hyperphosphatemia (>10 mg/dL) with reciprocal hypocalcemia.

Oyster: Calcium phosphate product >60 mg²/dL² carries high risk of metastatic calcification including cardiac and renal deposition. Avoid calcium administration unless symptomatic hypocalcemia with tetany or QTc >500 msec, as this may precipitate lethal calcium phosphate precipitation.[23]

Management Before Definitive Diagnosis

When STLS is suspected but malignancy not yet confirmed:

Immediate Interventions:

Aggressive hydration: 3 L/m²/day (200-300 mL/kg/day) targeting urine output >100 mL/m²/hour
Rasburicase: 0.1-0.2 mg/kg IV for uric acid >8 mg/dL (contraindicated in G6PD deficiency)
Correct electrolyte abnormalities: Avoid potassium and phosphate in fluids; calcium gluconate only for symptomatic hypocalcemia
Alkalinization controversial: No longer routinely recommended as may worsen calcium phosphate precipitation[24]
Early nephrology consultation: Many require CRRT for refractory hyperkalemia, hyperphosphatemia, or volume overload

Diagnostic Workup While Treating:

CT chest/abdomen/pelvis with contrast
Peripheral blood smear (may reveal circulating blasts)
Flow cytometry of peripheral blood
Lactate dehydrogenase (markedly elevated, often >1000 U/L)
Consider expedited bone marrow biopsy if diagnosis unclear

Clinical Pearl: Don't wait for tissue diagnosis to treat TLS. The syndrome is life-threatening, and aggressive management must begin immediately. However, avoid chemotherapy until diagnosis is confirmed, as treatment regimens differ substantially by malignancy type.

Liquid Biopsy (Circulating Tumor DNA) as a Future Diagnostic Tool in the ICU

Technology Overview

Liquid biopsy analyzes circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), exosomes, or tumor-educated platelets from peripheral blood. This represents a paradigm shift from tissue-based to blood-based cancer diagnostics.[25]

Advantages in the ICU Setting:

Non-invasive; minimal risk even in coagulopathic patients
Can detect molecularly heterogeneous tumors better than single-site biopsy
Rapid turnaround (24-72 hours for some assays)
Serial sampling to assess treatment response
May detect tumor when anatomically inaccessible

Current Limitations:

Sensitivity varies: 70-90% for metastatic cancers, lower for early-stage or low tumor burden[26]
Specificity challenges: Clonal hematopoiesis of indeterminate potential (CHIP) may produce false positives
Not yet standard of care for diagnosis (approved primarily for treatment selection in known cancers)
Cost: $3,000-$5,000 per comprehensive panel
Insurance coverage limited to specific approved indications

Clinical Applications Emerging in Critical Care

Cancer of Unknown Primary (CUP): When metastatic disease is evident but primary site unclear, tissue-of-origin assays using methylation patterns can predict primary site with 85-95% accuracy, guiding empiric therapy.[27] Guardant360, FoundationOne Liquid CDx, and other platforms are FDA-approved for companion diagnostics in advanced cancers.

Monitoring Treatment Response: ctDNA levels decline rapidly with effective therapy (half-life 16 minutes to 2 hours). In ICU patients receiving emergent chemotherapy, ctDNA can provide early evidence of response before radiographic changes, potentially guiding escalation or de-escalation decisions.[28]

Oyster: Liquid biopsy cannot replace tissue diagnosis for most scenarios. Pathological examination remains essential for tumor grading, immunohistochemistry, and complete molecular characterization. Consider liquid biopsy as complementary when tissue is difficult or dangerous to obtain.

Future Directions: Multi-Cancer Early Detection (MCED)

Pan-cancer screening tests detecting shared epigenetic signatures across >50 cancer types (e.g., Galleri, CancerSEEK) are in clinical trials. While designed for asymptomatic screening, MCED tests might eventually assist intensivists in detecting occult malignancy in patients with unexplained critical illness.[29]

Diagnostic Hack: If considering liquid biopsy in your institution, partner with medical oncology and molecular pathology. They can advise on appropriate test selection, interpretation, and integration with tissue-based diagnosis. Many tertiary centers now have molecular tumor boards that can assist with complex cases.

Initiating First-Line Chemotherapy in the Critically Ill Patient

Prognostic Considerations and Ethical Framework

The decision to initiate chemotherapy in critically ill patients requires integration of oncologic, critical care, and ethical considerations. Historical data showed dismal outcomes for patients requiring mechanical ventilation or vasopressors at cancer diagnosis, but contemporary outcomes have improved with better supportive care and targeted therapies.[30]

Favorable Prognostic Factors:

Highly chemosensitive malignancy (Burkitt lymphoma, ALL, germ cell tumors, SCLC)
Good performance status before acute decompensation
Reversible precipitant for ICU admission (TLS, infection, hemorrhage)
Single organ failure
Age <70 years
Absence of progressive end-organ dysfunction despite ICU support

Unfavorable Prognostic Factors:

Multi-organ failure requiring escalating support
Poor performance status (ECOG 3-4) before acute illness
Refractory shock requiring high-dose or multiple vasopressors
Active uncontrolled infection
Age >75 with significant comorbidities
Chemoresistant tumor histology[31]

Clinical Pearl: Use validated scoring systems. The ICU cancer mortality model incorporating SOFA score, performance status, and tumor burden predicts 28-day mortality. SOFA >12 with ECOG 3-4 before ICU admission predicts >90% mortality, potentially informing goals-of-care discussions.[32]

Chemotherapy-Specific Considerations in the ICU

Dose Modifications: Organ dysfunction necessitates chemotherapy dose adjustments:

Hepatic impairment: Reduce anthracyclines, taxanes, vinca alkaloids, irinotecan
Renal impairment: Reduce carboplatin, methotrexate, topotecan; avoid cisplatin if CrCl <60 mL/min
Drug interactions: Vasopressors, sedatives, and antimicrobials may have significant interactions with chemotherapy via CYP450 enzymes

Cardiac Monitoring:

Anthracyclines (doxorubicin, daunorubicin) cause dose-dependent cardiotoxicity; obtain baseline echo; avoid if EF <40%
Continuous telemetry for QT-prolonging agents (arsenic trioxide, tyrosine kinase inhibitors)

Infectious Risk:

Neutropenia nadir typically 7-14 days post-chemotherapy
Maintain empiric broad-spectrum antibiotics throughout treatment
Consider G-CSF prophylaxis (pegfilgrastim) 24 hours after chemotherapy completion
Avoid live vaccines; ensure herpes simplex/zoster prophylaxis with acyclovir

Oyster: "Split-dose" strategies can reduce acute toxicity in critically ill patients. For example, giving half the planned dose of R-CHOP and reassessing hemodynamic stability before completing the cycle may prevent catastrophic complications while preserving anti-tumor efficacy.[33]

Specific Scenarios

Burkitt Lymphoma with TLS: Initiate R-CODOX-M or R-hyper-CVAD within 24-48 hours after TLS control. These rapidly proliferating tumors double every 24 hours; delays significantly worsen prognosis. Close monitoring with q6h labs and aggressive supportive care is essential.[34]

Acute Promyelocytic Leukemia (APL) with DIC: Medical emergency requiring immediate ATRA (all-trans retinoic acid) 45 mg/m²/day even before cytogenetic confirmation if blast count elevated with coagulopathy. Add arsenic trioxide 0.15 mg/kg/day for low-intermediate risk. High-dose dexamethasone 10mg IV q12h reduces differentiation syndrome risk. Aggressive transfusion support targeting platelets >50,000, fibrinogen >150 mg/dL.[35]

Hypercalcemic Crisis: Often from squamous lung cancer, breast cancer, or multiple myeloma. Fluid resuscitation, calcitonin, bisphosphonates (zoledronic acid 4mg IV), and potentially denosumab (120mg SQ). Once calcium <12 mg/dL and patient stabilized, chemotherapy can prevent recurrence.[36]

Multidisciplinary Collaboration

Clinical Pearl: Establish ICU-oncology liaison protocols at your institution. Key elements:

Joint rounds for critically ill oncology patients
Rapid response team including oncologist for chemotherapy-related emergencies
Pharmacy expertise in chemotherapy dose adjustment for organ dysfunction
Palliative care integration for goals-of-care discussions
Ethics consultation availability for complex decision-making

Prognostic Communication: Be honest about uncertainties. Example language: "We've identified a cancer that is potentially curable with chemotherapy. However, your current critical illness increases treatment risks substantially. Our best estimate is X% chance of survival with treatment versus Y% without treatment. Let's discuss what matters most to you."

Conclusion

The diagnosis of occult malignancy in the ICU requires a synthesis of clinical pattern recognition, judicious use of invasive diagnostics, interpretation of laboratory derangements suggesting malignant processes, and integration of emerging molecular diagnostic technologies. The intensivist must balance diagnostic imperative against procedural risks, incorporating prognostic data and patient values into shared decision-making.

Key principles include:

Maintain high clinical suspicion for occult malignancy in idiopathic VTE, paraneoplastic syndromes, and unexplained organ failure
Blind biopsies (bone marrow, liver, skin) have substantial diagnostic yield in appropriate clinical contexts
Spontaneous tumor lysis syndrome may be the presenting manifestation of aggressive hematological malignancy
Liquid biopsy technologies show promise but currently complement rather than replace tissue diagnosis
Select patients with chemosensitive malignancies and reversible critical illness may benefit from early oncologic therapy despite ICU support requirements

As critical care oncology evolves, intensivists will increasingly serve as diagnostic gatekeepers for occult malignancy, requiring ongoing education in oncologic emergencies, molecular diagnostics, and the ethical complexities of cancer diagnosis in critical illness.

References

Taccone FS, et al. Characteristics and outcomes of cancer patients in European ICUs. Crit Care. 2009;13(1):R15.
Puxty K, et al. Risk of critical illness among patients with solid cancers. JAMA Oncol. 2015;1(8):1078-1085.
Carrier M, et al. Systematic review: case-fatality rates of recurrent VTE and major bleeding events among patients treated for VTE. Ann Intern Med. 2010;152(9):578-589.
Varki A. Trousseau's syndrome: multiple definitions and multiple mechanisms. Blood. 2007;110(6):1723-1729.
Prandoni P, et al. The risk of cancer in patients with acute VTE and extremely elevated D-dimer. Thromb Haemost. 2016;116(1):91-96.
Graus F, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 2004;75(8):1135-1140.
Titulaer MJ, et al. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol. 2011;10(12):1098-1107.
Dalmau J, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 2008;7(12):1091-1098.
Ilias I, et al. Cushing's syndrome due to ectopic ACTH secretion. J Clin Med. 2005;95(2):143-149.
Rowbotham D, et al. Acute liver failure secondary to hepatic infiltration. Gut. 1998;42(4):576-580.
Bruce DM, et al. Lymphangitic carcinomatosis as a cause of dyspnea. Can Respir J. 2012;19(3):e18-e20.
Hot A, et al. Yield of bone marrow examination in diagnosing the cause of fever of unknown origin. Arch Intern Med. 2009;169(21):2018-2023.
Paydas S. Bone marrow necrosis: causes and mechanisms. Int J Hematol. 2019;109(5):505-516.
Singh G, et al. Bilateral bone marrow examination in fever of unknown origin. J Assoc Physicians India. 2000;48(4):377-379.
Weiss L, et al. The role of liver biopsy in fever of unknown origin. Medicine. 1991;70(2):138-145.
Rowland R, et al. Hepatic infiltration as a presenting feature of acute lymphoblastic leukemia. Leukemia. 2003;17(12):2518-2519.
Ferreri AJM, et al. Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors. Lancet Oncol. 2004;5(1):38-47.
Henter JI, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124-131.
Fardet L, et al. Development and validation of the HScore for diagnosis of secondary HLH. Arthritis Rheumatol. 2014;66(9):2613-2620.
Howard SC, et al. The tumor lysis syndrome. N Engl J Med. 2011;364(19):1844-1854.
Cairo MS, et al. Recommendations for evaluation of risk and prophylaxis of tumor lysis syndrome. Br J Haematol. 2010;149(4):578-586.
Vaisban E, et al. Spontaneous tumor lysis syndrome in solid tumors. Am J Med Sci. 2003;325(1):38-40.
Hande KR, et al. Severe allopurinol toxicity. Am J Med. 1984;76(1):47-56.
Coiffier B, et al. Guidelines for management of tumor lysis syndrome in adults. Expert Rev Anticancer Ther. 2008;8(3):315-328.
Siravegna G, et al. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol. 2017;14(9):531-548.
Cohen JD, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science. 2018;359(6378):926-930.
Moran S, et al. Epigenetic profiling to classify cancer of unknown primary. JAMA. 2016;316(10):1063-1072.
Tie J, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence. Sci Transl Med. 2016;8(346):346ra92.
Liu MC, et al. Sensitive and specific multi-cancer detection from blood. Ann Oncol. 2021;32(9):1167-1177.
Azoulay E, et al. Outcomes of critically ill patients with hematologic malignancies. J Clin Oncol. 2013;31(25):2810-2818.
Mokart D, et al. Prognosis of neutropenic patients admitted to ICU. Crit Care. 2015;19(1):296.
Soares M, et al. Characteristics and outcomes of patients with cancer requiring admission to ICUs. Chest. 2010;138(6):1413-1421.
Aldoss I, et al. Dose-modified chemotherapy in elderly patients with acute lymphoblastic leukemia. Leuk Lymphoma. 2015;56(6):1691-1698.
Magrath I, et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome. J Clin Oncol. 1996;14(3):925-934.
Sanz MA, et al. Management of acute promyelocytic leukemia. Nat Rev Clin Oncol. 2009;6(2):87-96.
Stewart AF. Hypercalcemia associated with cancer. N Engl J Med. 2005;352(4):373-379.

Author's Note

This review synthesizes evidence-based approaches with practical clinical wisdom. Trainees should recognize that occult malignancy diagnosis remains an evolving field, with institutional variation in diagnostic algorithms. Local multidisciplinary collaboration and individualized patient assessment remain paramount.

learningmedicine

Friday, October 31, 2025